Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis

Journal of Clinical Pharmacology

Volumn 49, Issue 8, 2009, Pages 965-972

  De Miranda Silva, Carolina ^a   Dumět Fernandes, Bruno Joś ^a   Donadi, Eduardo Antǒnio ^a   Silva, Lucienir Maria ^a   Barbosa Coelho, Eduardo ^a   Dantas, Ḿrcio ^a   Marques, Maria Paula ^a   Lanchote, Vera Lucia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cyclophosphamide; Enantiomers; Lupus nephritis; Midazolam; Pharmacokinetics

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; AMITRIPTYLINE; AMLODIPINE; ATENOLOL; AZATHIOPRINE; BROMOPRIDE; CALCIUM CARBONATE; CAPTOPRIL; CHLOROQUINE; CLONIDINE; COLECALCIFEROL; CYCLOPHOSPHAMIDE; CYCRAM; DIPYRONE; ENALAPRIL; FLUOXETINE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYDROXYCHLOROQUINE; LOSARTAN; MESNA; METFORMIN; METHYLPREDNISOLONE; MIDAZOLAM; NIFEDIPINE; ONDANSETRON; PARACETAMOL; PREDNISONE; THYROXINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; ENANTIOMER; GLOMERULUS FILTRATION RATE; HUMAN; LIQUID CHROMATOGRAPHY; LUPUS ERYTHEMATOSUS NEPHRITIS; PHARMACOKINETICS; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; CREATININE; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLOMERULAR FILTRATION RATE; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LUPUS NEPHRITIS; MALE; MIDAZOLAM; MIDDLE AGED; STATISTICS, NONPARAMETRIC; STEREOISOMERISM; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 70349285260     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009337938     Document Type: Article

References (29)

1. Boumpas DT, Sidiropoulos P., Bertsias G. Optimum therapeutic approaches for lupus nephritis: what therapy and for whom ? Nat Clin Pract Rheumatol. 2005 ; 1: 22-30.
2. De Jonge ME, Huitema ADR, Rodenhuis S., Beijnen JH Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005 ; 44: 1135-1164.
3. Haubitz M., Bohnenstengel F., Brunkhorst R., Schwab M., Hofmann U., Busse D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int. 2002 ; 61: 1495-1501.
4. Williams ML, Wainer IW, Granvil CP, Gehrcke B., Bernstein ML, Ducharme M. Pharmacokinetics of (R)- and (S)-cyclophosphamide and their dechloroethylated metabolites in cancer patients. Chirality. 1999 ; 11: 301-308.
5. Cox PJ, Farmer PB, Jarman M., Jones M. Observations on the differential metabolism and biological activity of the optical isomers of cyclophosphamide. Biochem Pharmacol. 1976 ; 25: 993-996.
6. Kleinrok Z., Chmielewska B., Czuczwar JS, et al. Comparison of pharmacological properties of cyclophosphamide and its enantiomers. Arch Immunol Ther Exp. 1986 ; 34: 263-273. (Pubitemid 17014148)
7. Paprocka M., Kusnierczyk H., Budzynski W., Rak J., Radzikowski C. Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide: I. Antitumour affect of cyclophosphamide and ifosfamide enantiomers. Arch Immunol Ther Exp. 1986 ; 34: 275-284. (Pubitemid 17014149)
8. Jarman M., Milsted R., Smyth JF, Kinas RW, Pankiewicz K., Stec WJ Comparative metabolism of 2-[Bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2- oxazaphosphorine-2-oxide (cyclophosphamide) and its enantiomers in humans. Cancer Res. 1979 ; 39: 2762-2767.
9. Holm KA, Kindberg CG, Stobaugh JF, Slavik M., Riley CM Stereoselective pharmacokinetics and metabolism of the enantiomers of cyclophosphamide. Biochem Pharmacol. 1990 ; 39: 1375-1384.
10. Corlett SA, Chrystyn H. High-performance liquid chromatographic determination of the enantiomers of cyclophosphamide in serum. J Chromatogr B Biomed Appl. 1996 ; 682: 337-342.
11. Churchwell MD, Mueller BA Selected pharmacokinetic issues in patients with chronic kidney disease. Blood Purif. 2007 ; 25: 133-138.
12. Nolin TD, Frye RF, Matzke GR Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis. 2003 ; 42: 906-925.
13. Michaud J., Dub́ P., Naud J., et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol. 2005 ; 144: 1067-1077.
14. Mouridsen HT, Jacobsen E. Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacol Toxicol (Copenh). 1975 ; 36: 409-414.
15. Bramwell V., Calvert RT, Edwards G., Scarffe H., Crowther D. The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemother Pharmacol. 1979 ; 3: 253-259.
16. Juma FD, Rogers HJ, Trounce JR Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol. 1981 ; 19: 443-451.
17. Hochberg MC Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725.
18. US National Kidney Foundation. NKF K/DOQI GUIDELINES: K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. 2002. http://www.kidney.org/professionals/KDOQI/guidelines-ckd/ p4-class-g1.htm. Accessed November 10, 2008.
19. De Miranda Silva C., Dumet Fernandes BJ, Marques Pereira MP, et al. Determination of cyclophosphamide enantiomers in plasma by LC-MS/MS: application to pharmacokinetics in breast cancer and lupus nephritis patients. Chirality. 2008 ; 21: 383-389.
20. Jabor VA, Coelho EB, Santos NAG, Bonato PS, Lanchote VL A highly sensitive LC-MS-MS assay for analysis of midazolam and its major metabolite in human plasma: applications to drug metabolism. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 ; 822: 27-32.
21. Gabrielsson J., Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts & Applications. Stockholm: Swedish Pharmaceutical Press ; 2000.
22. Schellens JHM, Van Der Wart JHF, Danhof M., Van Der Velde EA, Breimer DD Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach. Br J Clin Pharmacol. 1988 ; 26: 373-384.
23. Gilbert CJ, Petros WP, Vredenburg J., et al. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol. 1998 ; 42: 497-503.
24. Faber OK, Mouridsen HT, Skovsted L. The biotransformation of cyclophosphamide in man: influence of prednisone. Acta Pharmacol Toxicol (Copenh). 1974 ; 35: 195-200.
25. Renton KW Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther. 2001 ; 92: 147-163.
26. Zhang J., Tian Q., Yung Chan S., et al. Metabolism and transport of oxazaphosphorines and clinical implications. Drug Metab Rev. 2005 ; 37: 611-703.
27. Wojnowski L., Kamdem LK Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol. 2006 ; 2: 171-182.
28. Chen M., Ma L., Drusano GL, Bertino JS Jr, Nafziger AN Sex differences in CYP3A activity using intravenous and oral midazolam. Clin Pharmacol Ther. 2006 ; 80: 531-538.
29. Kharasch ED, Walker A., Isoherranen N., et al. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther. 2007 ; 82: 410-426.